Ashkan M. Abbey, MD, FASRS, FAAO, of Texas Retina Associates in Dallas, moderated a recent Modern Retina Case-Based Roundtable on diagnosing and treating patients with macular telangiectasia type 2 ...

4DMT and Otsuka Pharmaceutical partner on 4D-150 in the greater Asia-Pacific region ...

Q&A: Sally S. Ong, MD on the neighborhood-level characteristics associated with delay in surgery and loss to follow-up ...

In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Zacks about ONL1204, a first-in-class Fas pathway inhibitor showing promise in ...

Discover key insights from the AAO 2025 meeting, highlighting advancements in real-world data, gene therapies, multitargeting treatments, and AI in retina care. Gene therapy revolutionizes retinal ...

The value of attending industry meetings at the beginning of a career in ophthalmology. Attending the American Academy of Ophthalmology (AAO) Annual Meeting for the first time can feel overwhelming.

Phase I/II safety and efficacy study currently enrolling. Atsena Therapeutics announced in a press release that the FDA granted its gene therapy product candidate, ATSN-201, the regenerative medicine ...

In her keynote address, Prof Schmidt-Erfurth focused on new artificial intelligence tools and their usage in addressing age-related macular degeneration. At this year's meeting of the European Society ...

Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement. In a ...

Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, ...

The results of a new retrospective cohort study suggest that use of curcuma-based nutritional supplements (CBNS) may be associated with the reduced risk of developing age-related macular degeneration ...

Curacle plans to finalize its development strategy, including phase 2b and 3 trials, through a Type C meeting with the US FDA in February of 2025. Curacle presented the results of its phase 2a ...